Abstract: Disclosed herein are polypeptides, and methods of making and using such polypeptides, that comprise a bispecific antibody construct covalently linked to an extended recombinant polypeptide comprising a barcode fragment releasable from said polypeptide upon digestion by a protease, and a Release Segment that can be proteolytically cleaved wherein said cleavage releases the bispecific antibody construct from the extended recombinant polypeptide.
Type:
Grant
Filed:
October 25, 2023
Date of Patent:
February 4, 2025
Assignee:
Amunix Pharmaceuticals, Inc.
Inventors:
Volker Schellenberger, Eric Johansen, Angela Henkensiefken, Darragh Maccann, James McClory, Philipp Kuhn, Andre Frenzel, Bryan Irving, Mika Derynck
Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
Type:
Grant
Filed:
January 15, 2021
Date of Patent:
August 27, 2024
Assignee:
AMUNIX PHARMACEUTICALS, INC.
Inventors:
Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
Abstract: The present invention relates to activatable recombinant polypeptide compositions comprising a cleavage release segment. In some instances, the activatable recombinant polypeptide compositions include an XTEN linked to binding moieties by cleavable release segments that, when cleaved, the binding moieties are capable of binding together effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable activatable recombinant compositions.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
August 13, 2024
Assignee:
AMUNIX PHARMACEUTICALS, INC.
Inventors:
Fan Yang, Volker Schellenberger, Vladimir Podust, Bee-Cheng Sim, Desiree Thayer, John Beaber
Abstract: The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.
Type:
Grant
Filed:
December 19, 2022
Date of Patent:
May 14, 2024
Assignee:
AMUNIX PHARMACEUTICALS, INC.
Inventors:
Volker Schellenberger, Fan Yang, Desiree Thayer, Bee-Cheng Sim, Chia-Wei Wang
Abstract: The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.
Type:
Grant
Filed:
August 26, 2016
Date of Patent:
August 1, 2023
Assignee:
AMUNIX PHARMACEUTICALS, INC.
Inventors:
Volker Schellenberger, Fan Yang, Desiree Thayer, Bee-Cheng Sim, Chia-Wei Wang
Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
Type:
Grant
Filed:
February 2, 2018
Date of Patent:
March 30, 2021
Assignee:
Amunix Pharmaceuticals, Inc
Inventors:
Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
Abstract: The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.
Abstract: The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
Type:
Grant
Filed:
April 17, 2018
Date of Patent:
December 22, 2020
Assignee:
Amunix Pharmaceuticals, Inc.
Inventors:
Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. C. Stemmer, Nathan C. Geething